Head and neck cancer who are eligible for concurrent chemoradiation with cisplatin Head and Neck Neoplasms, Cisplatin, Chemoradiotherapy, Nephrotoxicity, Acute Kidney Injury, Retrospective Studies, Cohort Studies, Kidney Function, Antineoplastic Combined Chemotherapy Protocols, Cisplatin Adverse Effects, Kidney Diseases
Conditions
Interventions
Receiving Cisplatin 100 mg/sq.m every 3 weeks with radiotherapy,Receiving Cisplatin 40 mg/sq.m every week with radiotherapy
Supportive Care,Supportive Care
Cisplatin Triweekly regimen,Cisplatin Weekly regimen
Sponsors
Department of Medicine, Maharat Nakhon Ratchasima Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosed with head and neck cancer and treated with cisplatin-based chemotherapy concurrent with radiotherapy at Maharat Nakhon Ratchasima Hospital.
Exclusion criteria
Exclusion criteria: 1. Patients with recurrent cancer or those who have previously completed treatment with cisplatin, 2. Incomplete medical records, such as missing creatinine levels or other essential data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Acute Kidney Injury (AKI) During treatment and up to 1 month AKI will be assessed based on serum creatinine levels using the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cisplatin Cumulative Dose At the completion of chemotherapy Total cumulative dose of cisplatin recorded from patient treatment data.,Factors Associated with Cisplatin Nephrotoxicity At the completion of data collection. Multivariable logistic regression analysis will assess risk factors such as age, body mass index (BMI), and baseline renal function. | — |
Countries
Thailand
Contacts
Public ContactJirawat Thanestada
Maharat Nakhon Ratchasima hospital
Outcome results
None listed